Dendritic cell immunotherapy: mapping the way
Dendritic cell immunotherapy: mapping the way
复制标题
DOI：
10.1038/nm1039
复制
发表时间：
2004-05-01
期刊：
影响因子：
82.9
通讯作者：
Melief, CJM
中科院分区：
文献类型：
--
作者：
Figdor, CG;de Vries, IJM;Melief, CJM
树突状细胞（Dendritic cells，DC）是免疫系统中专职的抗原提呈细胞，具有刺激或抑制免疫应答的潜能。利用树突状细胞的免疫调节能力对于治疗癌症、自身免疫性疾病和预防移植排斥有着巨大的希望。虽然早期临床试验表明DC疫苗可以在一些癌症患者中诱导免疫应答，但需要仔细的研究设计和使用标准化的临床和免疫学标准。
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.